Next Article in Journal
Acellular Pertussis Vaccine Components: Today and Tomorrow
Next Article in Special Issue
Myxoma Virus-Encoded Host Range Protein M029: A Multifunctional Antagonist Targeting Multiple Host Antiviral and Innate Immune Pathways
Previous Article in Journal
Identification of Novel Adjuvants for Ebola Virus-Like Particle Vaccine
Previous Article in Special Issue
Recombinant Live Attenuated Influenza Vaccine Viruses Carrying Conserved T Cell Epitopes of Human Adenoviruses Induce Functional Cytotoxic T Cell Responses and Protect Mice against both Infections
Open AccessReview

Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B

1
Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, Casablanca 20250, Morocco
2
Transboundary Animal Diseases Centre, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima 890-0065, Japan
3
Department of Microbiology and Public Health, Faculty of Animal Science and Veterinary Medicine, Patuakhali Science and Technology University, Barishal 8210, Bangladesh
4
Department of Microbiology and Cell Biology, The Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan
*
Authors to whom correspondence should be addressed.
Vaccines 2020, 8(2), 216; https://doi.org/10.3390/vaccines8020216
Received: 18 March 2020 / Revised: 15 April 2020 / Accepted: 16 April 2020 / Published: 11 May 2020
(This article belongs to the Special Issue Virus Immune Escape and Host Immune System)
Despite the availability of an effective preventive vaccine for hepatitis B virus (HBV) for over 38 years, chronic HBV (CHB) infection remains a global health burden with around 257 million patients. The ideal treatment goal for CHB infection would be to achieve complete cure; however, current therapies such as peg-interferon and nucleos(t)ide analogs are unable to achieve the functional cure, the newly set target for HBV chronic infection. Considering the fact functional cure has been accepted as an endpoint in the treatment of chronic hepatitis B by scientific committee, the development of alternative therapeutic strategies is urgently needed to functionally cure CHB infection. A promising target for future therapeutic strategies is immune modulation to restore dysfunctional HBV-specific immunity. In this review, we provide an overview of the progress in alternative therapeutic strategies, including immune-based therapeutic approaches that enhance host innate and adaptive immunity to achieve and increase the functional cure from CHB infection. View Full-Text
Keywords: HBV; innate immunity; adaptive immunity; host factors; therapeutic vaccine HBV; innate immunity; adaptive immunity; host factors; therapeutic vaccine
MDPI and ACS Style

Ezzikouri, S.; Hoque Kayesh, M.E.; Benjelloun, S.; Kohara, M.; Tsukiyama-Kohara, K. Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B. Vaccines 2020, 8, 216. https://doi.org/10.3390/vaccines8020216

AMA Style

Ezzikouri S, Hoque Kayesh ME, Benjelloun S, Kohara M, Tsukiyama-Kohara K. Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B. Vaccines. 2020; 8(2):216. https://doi.org/10.3390/vaccines8020216

Chicago/Turabian Style

Ezzikouri, Sayeh; Hoque Kayesh, Mohammad E.; Benjelloun, Soumaya; Kohara, Michinori; Tsukiyama-Kohara, Kyoko. 2020. "Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B" Vaccines 8, no. 2: 216. https://doi.org/10.3390/vaccines8020216

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop